Mitochondrial-targeted and ROS-responsive nanocarrier <i>via</i> nose-to-brain pathway for ischemic stroke treatment.

Authors:
Zhang Y; Zhang H; Zhao F; Jiang Z; Cui Y and 3 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.06.011

PMCID:
PMC10692350

PMID:
38045064

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation o…
Wang M; Wang W; You S and 6 more (2023) - Transparency Score: 3/6
Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of …
Sun X; Xu X; Wang J and 8 more (2023) - Transparency Score: 3/6
Activation of insulin-like growth factor-1 receptor (IGF-1R) promotes growth of colorectal cancer t…
Xie Q; Chu Y; Yuan W and 7 more (2023) - Transparency Score: 3/6
Activation of PXR causes drug interactions with Paxlovid in transgenic mice.
Lei S; Guo A; Lu J and 4 more (2023) - Transparency Score: 3/6
Adiponectin restores the obesity-induced impaired immunomodulatory function of mesenchymal stromal …
Pham DV; Nguyen TK; Nguyen BL and 4 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest The authors declare no competing financial interest."

Evidence found in paper:

"This work was supported by 10.13039/100014717National Natural Science Foundation (82272154, China), Tianjin Science Fund for Distinguished Young Scholars (22JCJQJC00120, China), Natural Science Foundation of Tianjin (The Basic Research Cooperation Special Foundation of Beijing-Tianjin-Hebei Region, H2022205047, 22JCZXJC00060, and E3B33911DF, China), the 10.13039/501100012226Fundamental Research Funds for the Central Universities (3332021068, 3332020059, 2019PT320028, and 2021-RC310-005, China), and the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-058, and 2022-I2M-2-003, China)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025